ViewPoint Therapeutics Raises $35 Million in Series B Financing
-- Proceeds will advance lead product candidate through clinical proof-of-concept studies in cataracts and presbyopia --
-- Series B led by The Rise Fund, a global impact fund --
SAN FRANCISCO, March 05, 2018 (GLOBE NEWSWIRE) -- ViewPoint Therapeutics, Inc., a privately-held biotechnology company pioneering the development of crystallin stabilizers to prevent and treat cataracts and presbyopia, today announced the closing of a $35 million Series B financing. The financing was led b...